Elevated Serum Growth Differentiation Factor 15 Levels as a Potential Biomarker of the Efficacy of Imeglimin in Individuals With Type 2 Diabetes Mellitus: An Exploratory Study
Three-month imeglimin treatment increased serum GDF15 levels in clinical type 2 diabetes mellitus patients along with little change in basal metabolism or body composition, suggesting GDF15 as a potential marker for the efficacy of imeglimin.
Authors
- Satoko Nomura
- Yoshihito Shimada
- Kanae Asai
- Shinobu Oshima
- Kentaro Sakaki
- Naoki Wada (ORCID: https://orcid.org/0000-0003-4271-4039)
- Norio Harada (ORCID: https://orcid.org/0000-0001-8720-1013)
- Ryoko Fujiwara (ORCID: https://orcid.org/0000-0001-9619-4783)
- Erina Joo
- Takaaki Murakami (ORCID: https://orcid.org/0000-0003-3844-1138)
- Nobuya Inagaki (ORCID: https://orcid.org/0000-0001-8261-2593)
- Daisuke Yabe (ORCID: https://orcid.org/0000-0002-5334-7687)
- Kenichiro Shide
- Michiko Mori
- Ayako Oshima (ORCID: https://orcid.org/0000-0002-5946-6150)
- Keiko Wada
- Muhammad Fauzi (ORCID: https://orcid.org/0009-0008-5299-4277)
Institutions
- University of Fukui (JP)
- Kyoto University (JP)
- Kyoto University Hospital (JP)
- Kitano Hospital (JP)
Publication Details
- Journal
- Journal of Clinical Medicine Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.14740/jocmr6031
- Citations
- 2
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Eli Lilly and Company
- Sanofi
- Kowa Company
- Kissei
- Boehringer Ingelheim Japan
- Daiichi-Sankyo
- Novo Nordisk
- Astellas Pharma
- Teijin Pharma
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- Novartis Pharma
- Eli Lilly Japan
- Novo Nordisk Pharma
- Daiichi Sankyo Europe